Incyte Corp INCY:NASDAQ

Last Price$87.75NASDAQ Previous Close - Last Trade as of 4:00PM ET 4/08/20

Today's Change+1.09(1.26%)
Bid (Size)$87.75 (2)
Ask (Size)$88.30 (5)
Day Low / High$85.95 - 88.59
Volume2.1 M
 

View Biotechnology IndustryPeer Comparison as of 04/08/2020

 

Incyte Corp ( NASDAQ )

Price: $87.75
Change: +1.09 (1.26%)
Volume: 2.1 M
4:00PM ET 4/08/2020
 
 

Seattle Genetics Inc ( NASDAQ )

Price: $119.68
Change: -2.19 (1.80%)
Volume: 1.2 M
4:00PM ET 4/08/2020
 
 

Alexion Pharmaceuticals Inc ( NASDAQ )

Price: $98.56
Change: +3.84 (4.05%)
Volume: 2.5 M
4:00PM ET 4/08/2020
 
 

Agilent Technologies Inc ( NYSE )

Price: $76.68
Change: -0.01 (0.01%)
Volume: 1.00
4:00PM ET 4/08/2020
 
 

Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $79.60
Change: -0.23 (0.29%)
Volume: 1.5 M
4:00PM ET 4/08/2020
 

Read more news Recent News

Insider Trends: Incyte Sees 90 Days of Insider Buying Trend Reducing with Share Disposition
4:42PM ET 4/08/2020 MT Newswires

On Apr 06, 2020, Maria E Pasquale, EVP & General Counsel, sold 1,842 shares in Incyte (INCY) for $156,570. Pasquale, after the transactions described in...

Analyst Actions: Oppenheimer Raises Incyte's Price Target to $90 From $85 on Probability of Success for Topical Ruxolotinib, Keeps Outperform Rating
9:31AM ET 4/07/2020 MT Newswires

Incyte (INCY) has an average buy rating among analysts with an average price target of $91. Price: 87.86, Change: +2.75, Percent Change: +3.23 ...

Incyte Plans to Submit New Drug Application for Eczema Cream Following Phase Three Testing
1:48PM ET 4/06/2020 MT Newswires

Shares of Incyte (INCY) said on Monday that data from a study of its cream for eczema -- Atopic Dermatitis -- supports a plan for the company to submit a...

Sector Update: Health Care Stocks Outperform Broader Markets This Afternoon
3:59PM ET 4/03/2020 MT Newswires

Top Health Care Stocks JNJ -0.53% PFE +1.86% ABT -0.40% MRK -1.44% AMGN -2.25% Health care stocks continued their slide this afternoon, with the NYSE...

Company Profile

Business DescriptionIncyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE. View company web site for more details
Address1801 Augustine Cut-Off
Wilmington, Delaware 19803
Phone+1.302.498.6700
Number of Employees1,367
Recent SEC Filing04/08/20204
Chairman, President & Chief Executive OfficerHervé Hoppenot
Chief Financial Officer & Executive Vice PresidentChristiana Stamoulis
Chief Medical Officer & Executive Vice PresidentSteven H. Stein
Chief Scientific Officer & Executive VPDashyant Dhanak

Company Highlights

Price Open$86.74
Previous Close$87.75
52 Week Range$62.48 - 96.79
Market Capitalization$19.0 B
Shares Outstanding216.8 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement05/05/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings38.34
Earnings per Share$2.01
Beta vs. S&P 500N/A
Revenue$1.9 B
Net Profit Margin20.70%
Return on Equity19.11%

Analyst Ratings as of 04/01/2020

Buy
12
Overweight
1
Hold
8
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset